0001531177false00015311772025-01-242025-01-24

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 24, 2025

 

 

Sight Sciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40587

80-0625749

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

4040 Campbell Avenue

Suite 100

 

Menlo Park, California

 

94025

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 877 266-1144

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

SGHT

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Compensatory Arrangements of Certain Executive Officers

On January 24, 2025, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Sight Sciences, Inc. (the “Company”) approved annual base salaries and target cash incentive bonus opportunities for the fiscal year ending December 31, 2025 (“Fiscal 2025”) for certain of the Company’s executive officers, including Paul Badawi, the Company’s President and Chief Executive Officer, Alison Bauerlein, the Company’s Chief Financial Officer and Treasurer, and Matthew Link, the Company’s Chief Commercial Officer.

 

Fiscal 2025 Base Salary

The annual base salary amounts received for the fiscal year ended December 31, 2024 (“Fiscal 2024”) and to be received for Fiscal 2025 by Mr. Badawi, Ms. Bauerlein, and Mr. Link are set forth opposite their names in the table below:

 

Name

Annual Base Salary (Fiscal 2024)

Annual Base Salary (Fiscal 2025)

Paul Badawi

$640,000

$659,000

Alison Bauerlein

$450,000

$473,000

Matthew Link

$420,000

$433,000

 

Fiscal 2025 Cash Incentive Program

The Company maintains an annual cash incentive program for all employees who are not eligible for commissions and who are otherwise eligible to participate in the program, including Mr. Badawi, Ms. Bauerlein, and Mr. Link.

The target bonus opportunity is set as a percentage of the participant’s base salary for the year as determined by the Compensation Committee. The Compensation Committee approved the following Fiscal 2025 target bonus opportunities for Mr. Badawi, Ms. Bauerlein, and Mr. Link, as set forth opposite their respective names in the table below:

 

Name

Target Bonus Opportunity Percentage

Paul Badawi

75%

Alison Bauerlein

60%

Matthew Link

50%

 

The Fiscal 2025 cash incentive program applicable to executive officers will be earned based exclusively on achievement by the Company of specified predetermined milestones relating to revenue, adjusted operating expense, key market access milestones, key clinical and R&D milestones, and key commercial launch milestones.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Sight Sciences, Inc.

 

 

 

 

Date:

January 28, 2025

By:

/s/ Alison Bauerlein

 

 

 

Chief Financial Officer

 

v3.24.4
Document And Entity Information
Jan. 24, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 24, 2025
Entity Registrant Name Sight Sciences, Inc.
Entity Central Index Key 0001531177
Entity Emerging Growth Company true
Entity File Number 001-40587
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 80-0625749
Entity Address, Address Line One 4040 Campbell Avenue
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Menlo Park
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94025
City Area Code 877
Local Phone Number 266-1144
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SGHT
Security Exchange Name NASDAQ
Grafico Azioni Sight Sciences (NASDAQ:SGHT)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Sight Sciences
Grafico Azioni Sight Sciences (NASDAQ:SGHT)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Sight Sciences